Small Molecule Inhibitors of the Candida albicans Budded-to-Hyphal Transition Act through Multiple Signaling Pathways
2011

Inhibitors of Candida albicans Growth Transition

Sample size: 12 publication 10 minutes Evidence: moderate

Author Information

Author(s): Midkiff John, Borochoff-Porte Nathan, White Dylan, Johnson Douglas I.

Primary Institution: University of Vermont

Hypothesis

The study investigates the efficacy of small molecules in inhibiting the budded-to-hyphal transition (BHT) in Candida albicans through various signaling pathways.

Conclusion

The study identifies several small molecules that can inhibit the budded-to-hyphal transition in Candida albicans, suggesting potential therapeutic applications.

Supporting Evidence

  • The study identified 21 small molecules that could inhibit the C. albicans BHT.
  • Chemical epistasis analyses suggested that most BHT inhibitors acted through the Efg1 or Cph1 pathways.
  • Clozapine, an FDA-approved drug, was shown to inhibit the BHT by acting on the Gpr1 receptor.

Takeaway

Researchers found some drugs that can stop a yeast called Candida albicans from changing its shape, which is important for its growth and ability to cause infections.

Methodology

The study used various hyphal-inducing media to test the effects of 12 BHT inhibitors on Candida albicans growth.

Limitations

The study primarily focused on a limited number of signaling pathways and small molecules, which may not encompass all potential inhibitors.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0025395

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication